Management of Peyronie’s disease: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)
Open Access
- 8 December 2025
- journal article
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (1)
Abstract
Introduction: There is no ideal treatment for Peyronie’s Disease (PD) since every patient has different needs with varying perceived risks versus benefits of individual treatment options, coupled with the degree of impact relating to PD on sexual function and beyond. Objectives: The 5th International Consultation on Sexual Medicine (ICSM) guideline on PD provides an update to the previous ICSM with an aim to provide a clinical framework and best-evidenced consensus recommendations to assist clinicians in managing PD. Methodology: Available literature was reviewed, and a modified Delphi consensus was undertaken by leading sexual medicine experts to achieve a set of Quality of Evidence and strength of recommendations. This guideline was developed as an authoritative best-evidenced consensus incorporating state-of-the-art knowledge and contemporary literature. Results: A total of thirty-one recommendations were made on PD guidelines. New updates to the 4th ICSM on PD have been made in definition, pathophysiology, and treatment strategies. The presence of penile pain with erection could occur in the chronic phase due to torque or stretch on the penile scar and surrounding tissue. Oral therapy works best during the acute phase and should be provided concurrently with other treatment modalities. Penile traction therapy can reduce penile deformity as monotherapy or may be offered as part of a multimodal therapy approach. There is no convincing evidence supporting cellular-based therapy. The type of plication procedure used depends on the surgeon and patient preference, although excision of the tunica followed by plication may have a higher complication rate. There is currently no ideal graft, and graft contracture can occur postoperatively. Adjunctive procedures such as penile modeling, tunical plication, plaque incision/excision and grafting can be performed when penile deformity and/or penile curvature persist following penile prosthesis implantation. Conclusions: The management of PD should be individualized based on the patient’s needs and preferences while balancing the benefits and risks of each treatment option.Keywords
This publication has 332 references indexed in Scilit:
- Non-surgical therapies for Peyronie's diseaseCochrane Database of Systematic Reviews, 2023
- Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie’s disease: a review of the literatureWorld Journal of Urology, 2019
- A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s diseaseWorld Journal of Urology, 2019
- Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyondWorld Journal of Urology, 2019
- A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubricWorld Journal of Urology, 2019
- Tamoxifen Inhibits TGF‐β‐Mediated Activation of Myofibroblasts by Blocking Non‐Smad Signaling Through ERK1/2Journal of Cellular Physiology, 2015
- Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled studyInternational Urology and Nephrology, 2009
- The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie’s diseaseInternational Urology and Nephrology, 2008
- A Pilot Study Demonstrating Clinical Benefit From Intralesional Interferon Alpha 2B in the Treatment of Peyronie's DiseaseJournal of Andrology, 1999
- Collagenase for Peyronie's disease experimental studiesUrological Research, 1982